Selected research
Industry Research
Epoprostenol Industry Research Report 2026
Market perspective
The global Epoprostenol market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Epoprostenol is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Epoprostenol is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Epoprostenol is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Epoprostenol include Teva Parenteral, Merck, Glaxosmithkline Inc, Bayer AG, SteadyMed, Sandoz Canada Incorporated, Reata Pharmaceuticals, Arena Pharmaceuticals and Actelion, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Epoprostenol market in terms of revenue (US$ million) and, where applicable, sales volume (tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Epoprostenol Market by Company
Teva Parenteral
Merck
Glaxosmithkline Inc
Bayer AG
SteadyMed
Sandoz Canada Incorporated
Reata Pharmaceuticals
Arena Pharmaceuticals
Actelion
Epoprostenol Segment by Type
Oral Epoprostenol
Injection Epoprostenol
Epoprostenol Segment by Application
Retail Pharmacy
Online Pharmacy
Hospital Pharmacy
Epoprostenol Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epoprostenol market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Epoprostenol and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epoprostenol.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Epoprostenol manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Epoprostenol by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Epoprostenol in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Epoprostenol
- Injection Epoprostenol
Applications
- Retail Pharmacy
- Online Pharmacy
- Hospital Pharmacy
Companies covered
- Teva Parenteral
- Merck
- Glaxosmithkline Inc
- Bayer AG
- SteadyMed
- Sandoz Canada Incorporated
- Reata Pharmaceuticals
- Arena Pharmaceuticals
- Actelion
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Epoprostenol Market Size (2021-2032)
- 2.2.2 Global Epoprostenol Sales (2021-2032)
- 2.2.3 Global Epoprostenol Market Average Price (2021-2032)
- 2.3 Epoprostenol by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral Epoprostenol
- 2.3.3 Injection Epoprostenol
- 2.4 Epoprostenol by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacy
- 2.4.3 Online Pharmacy
- 2.4.4 Hospital Pharmacy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Epoprostenol Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Epoprostenol Sales (tons) of Manufacturers (2021-2026)
- 3.3 Global Epoprostenol Revenue of Manufacturers (2021-2026)
- 3.4 Global Epoprostenol Average Price by Manufacturers (2021-2026)
- 3.5 Global Epoprostenol Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Epoprostenol, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Epoprostenol, Product Type & Application
- 3.8 Global Manufacturers of Epoprostenol, Established Date
- 3.9 Global Epoprostenol Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Parenteral
- 4.1.1 Teva Parenteral Company Information
- 4.1.2 Teva Parenteral Business Overview
- 4.1.3 Teva Parenteral Epoprostenol Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Parenteral Epoprostenol Product Portfolio
- 4.1.5 Teva Parenteral Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck Epoprostenol Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck Epoprostenol Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Glaxosmithkline Inc
- 4.3.1 Glaxosmithkline Inc Company Information
- 4.3.2 Glaxosmithkline Inc Business Overview
- 4.3.3 Glaxosmithkline Inc Epoprostenol Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Glaxosmithkline Inc Epoprostenol Product Portfolio
- 4.3.5 Glaxosmithkline Inc Recent Developments
- 4.4 Bayer AG
- 4.4.1 Bayer AG Company Information
- 4.4.2 Bayer AG Business Overview
- 4.4.3 Bayer AG Epoprostenol Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bayer AG Epoprostenol Product Portfolio
- 4.4.5 Bayer AG Recent Developments
- 4.5 SteadyMed
- 4.5.1 SteadyMed Company Information
- 4.5.2 SteadyMed Business Overview
- 4.5.3 SteadyMed Epoprostenol Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 SteadyMed Epoprostenol Product Portfolio
- 4.5.5 SteadyMed Recent Developments
- 4.6 Sandoz Canada Incorporated
- 4.6.1 Sandoz Canada Incorporated Company Information
- 4.6.2 Sandoz Canada Incorporated Business Overview
- 4.6.3 Sandoz Canada Incorporated Epoprostenol Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sandoz Canada Incorporated Epoprostenol Product Portfolio
- 4.6.5 Sandoz Canada Incorporated Recent Developments
- 4.7 Reata Pharmaceuticals
- 4.7.1 Reata Pharmaceuticals Company Information
- 4.7.2 Reata Pharmaceuticals Business Overview
- 4.7.3 Reata Pharmaceuticals Epoprostenol Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Reata Pharmaceuticals Epoprostenol Product Portfolio
- 4.7.5 Reata Pharmaceuticals Recent Developments
- 4.8 Arena Pharmaceuticals
- 4.8.1 Arena Pharmaceuticals Company Information
- 4.8.2 Arena Pharmaceuticals Business Overview
- 4.8.3 Arena Pharmaceuticals Epoprostenol Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Arena Pharmaceuticals Epoprostenol Product Portfolio
- 4.8.5 Arena Pharmaceuticals Recent Developments
- 4.9 Actelion
- 4.9.1 Actelion Company Information
- 4.9.2 Actelion Business Overview
- 4.9.3 Actelion Epoprostenol Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Actelion Epoprostenol Product Portfolio
- 4.9.5 Actelion Recent Developments
5 Global Epoprostenol Market Scenario by Region
- 5.1 Global Epoprostenol Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Epoprostenol Sales by Region: 2021-2032
- 5.2.1 Global Epoprostenol Sales by Region: 2021-2026
- 5.2.2 Global Epoprostenol Sales by Region: 2027-2032
- 5.3 Global Epoprostenol Revenue by Region: 2021-2032
- 5.3.1 Global Epoprostenol Revenue by Region: 2021-2026
- 5.3.2 Global Epoprostenol Revenue by Region: 2027-2032
- 5.4 North America Epoprostenol Market Facts & Figures by Country
- 5.4.1 North America Epoprostenol Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Epoprostenol Sales by Country (2021-2032)
- 5.4.3 North America Epoprostenol Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Epoprostenol Market Facts & Figures by Country
- 5.5.1 Europe Epoprostenol Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Epoprostenol Sales by Country (2021-2032)
- 5.5.3 Europe Epoprostenol Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Epoprostenol Market Facts & Figures by Country
- 5.6.1 Asia Pacific Epoprostenol Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Epoprostenol Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Epoprostenol Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Epoprostenol Market Facts & Figures by Country
- 5.7.1 South America Epoprostenol Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Epoprostenol Sales by Country (2021-2032)
- 5.7.3 South America Epoprostenol Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Epoprostenol Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Epoprostenol Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Epoprostenol Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Epoprostenol Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Epoprostenol Sales by Type (2021-2032)
- 6.1.1 Global Epoprostenol Sales by Type (2021-2032) & (tons)
- 6.1.2 Global Epoprostenol Sales Market Share by Type (2021-2032)
- 6.2 Global Epoprostenol Revenue by Type (2021-2032)
- 6.2.1 Global Epoprostenol Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Epoprostenol Revenue Market Share by Type (2021-2032)
- 6.3 Global Epoprostenol Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Epoprostenol Sales by Application (2021-2032)
- 7.1.1 Global Epoprostenol Sales by Application (2021-2032) & (tons)
- 7.1.2 Global Epoprostenol Sales Market Share by Application (2021-2032)
- 7.2 Global Epoprostenol Revenue by Application (2021-2032)
- 7.2.1 Global Epoprostenol Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Epoprostenol Revenue Market Share by Application (2021-2032)
- 7.3 Global Epoprostenol Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Epoprostenol Value Chain Analysis
- 8.1.1 Epoprostenol Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Epoprostenol Production Mode & Process
- 8.2 Epoprostenol Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Epoprostenol Distributors
- 8.2.3 Epoprostenol Customers
9 Global Epoprostenol Analyzing Market Dynamics
- 9.1 Epoprostenol Industry Trends
- 9.2 Epoprostenol Industry Drivers
- 9.3 Epoprostenol Industry Opportunities and Challenges
- 9.4 Epoprostenol Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst